DAT x adrenergic receptor x σ1 receptor x NMDA receptor x CYP2D6

Main research purpose: Dextromethorphan bupropion sustained-release tablets (specification: 45 mg (calculated as C18H25NO·HBr·H2O)/105mg (calculated as C13H18ClNO·HCl)) developed and produced by Jiangsu Enhua Pharmaceutical Co., Ltd. The preparation under test is dextromethorphan and bupropion sustained-release tablets (AUVELITY®), which is licensed by Axsome Company and manufactured by Patheon Company. Specifications: 45 mg (based on C18H25NO·HBr·H2O)/105mg (based on C13H18ClNO· HCl (calculated as HCl)) is a reference preparation. The absorption rate and degree of absorption of the two preparations were studied in Chinese healthy adult subjects after a single oral administration on an empty stomach or after a meal, to evaluate the bioequivalence between the two preparations and to provide reference for formal trials. Secondary study objectives: To evaluate the safety of healthy subjects after a single fasting/postprandial oral administration of the test formulation and reference formulation of dextromethorphan bupropion extended-release tablets.